Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCRNASDAQ:IMVTNASDAQ:KRYSNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$29.54+4.0%$28.80$23.15▼$59.82$1.48B0.75428,264 shs283,716 shsIMVTImmunovant$14.55+3.8%$16.38$12.72▼$34.47$2.47B0.751.21 million shs1.05 million shsKRYSKrystal Biotech$139.43+5.5%$170.75$131.71▼$219.34$3.82B0.79299,353 shs335,707 shsRVMDRevolution Medicines$41.88+3.6%$37.40$29.17▼$62.40$7.80B1.111.49 million shs1.76 million shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore+4.01%-3.56%+11.09%+4.75%-49.89%IMVTImmunovant+3.78%-4.40%-0.89%-24.77%-50.49%KRYSKrystal Biotech+5.45%-14.09%-15.50%-7.00%-9.91%RVMDRevolution Medicines+3.20%+5.25%+17.25%+1.04%+12.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore3.2146 of 5 stars4.31.00.00.03.54.20.0IMVTImmunovant2.3082 of 5 stars4.50.00.00.03.21.70.0KRYSKrystal Biotech4.9291 of 5 stars4.53.00.04.72.83.31.9RVMDRevolution Medicines4.3772 of 5 stars4.50.00.04.74.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.50Moderate Buy$58.1396.77% UpsideIMVTImmunovant 2.90Moderate Buy$38.33163.46% UpsideKRYSKrystal Biotech 3.00Buy$218.6356.80% UpsideRVMDRevolution Medicines 3.00Buy$67.1760.38% UpsideCurrent Analyst Ratings BreakdownLatest KRYS, IMVT, IMCR, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$310.20M4.77N/AN/A$7.42 per share3.98IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/AKRYSKrystal Biotech$333.45M12.08$3.54 per share39.38$32.85 per share4.24RVMDRevolution Medicines$742K10,513.01N/AN/A$11.09 per share3.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%N/AIMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)KRYSKrystal Biotech$10.93M$4.1646.6313.83N/A30.69%11.41%10.40%N/ARVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%N/ALatest KRYS, IMVT, IMCR, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.033.783.76IMVTImmunovantN/A6.046.04KRYSKrystal BiotechN/A7.287.76RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%IMVTImmunovant47.08%KRYSKrystal Biotech86.29%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%IMVTImmunovant5.90%KRYSKrystal Biotech13.70%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.07 million45.48 millionOptionableIMVTImmunovant120169.86 million159.84 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableRVMDRevolution Medicines250186.26 million154.76 millionOptionableKRYS, IMVT, IMCR, and RVMD HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Reduces Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)May 13 at 7:14 AM | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 248,326 Revolution Medicines, Inc. (NASDAQ:RVMD)May 13 at 5:05 AM | marketbeat.comResearch Analysts Issue Forecasts for RVMD FY2025 EarningsMay 13 at 3:11 AM | americanbankingnews.comLeerink Partnrs Has Positive Outlook of RVMD FY2025 EarningsMay 13 at 2:56 AM | marketbeat.comWedbush Expects Reduced Earnings for Revolution MedicinesMay 13 at 1:31 AM | marketbeat.comFred Alger Management LLC Sells 392,547 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 12 at 5:35 AM | marketbeat.comAmeriprise Financial Inc. Acquires 141,426 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 12 at 4:15 AM | marketbeat.comFarallon Capital Management LLC Boosts Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 11 at 7:39 AM | marketbeat.comAlgert Global LLC Buys 6,925 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 11 at 4:57 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Stake Boosted by Schonfeld Strategic Advisors LLCMay 11 at 4:41 AM | marketbeat.comRevolution Medicines' (RVMD) "Buy" Rating Reiterated at Needham & Company LLCMay 11 at 1:39 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given "Buy" Rating at Needham & Company LLCMay 10 at 8:06 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is DAFNA Capital Management LLC's 3rd Largest PositionMay 10 at 7:30 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Deerfield Management Company L.P. Series C's 7th Largest PositionMay 10 at 7:26 AM | marketbeat.comDimensional Fund Advisors LP Sells 6,698 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 10 at 3:45 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Up on Analyst UpgradeMay 10 at 1:05 AM | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Brevan Howard Capital Management LPMay 9, 2025 | marketbeat.comNorthern Trust Corp Has $67.36 Million Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)May 9, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Rating of "Buy" from BrokeragesMay 9, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Holdings Cut by Casdin Capital LLCMay 8, 2025 | marketbeat.comRevolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS, IMVT, IMCR, and RVMD Company DescriptionsImmunocore NASDAQ:IMCR$29.54 +1.14 (+4.01%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$29.53 -0.01 (-0.03%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Immunovant NASDAQ:IMVT$14.55 +0.53 (+3.78%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$14.41 -0.14 (-0.96%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Krystal Biotech NASDAQ:KRYS$139.43 +7.25 (+5.48%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$138.50 -0.93 (-0.67%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Revolution Medicines NASDAQ:RVMD$41.88 +1.46 (+3.61%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$40.41 -1.47 (-3.50%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
